BioCryst Pharmaceuticals

Quick facts

Phase 3 pipeline

• BCX7353 capsules · Immunology / Rare Disease
  BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.

Phase 2 pipeline

• BCX4161 · Immunology
  BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system.
• BCX4208 · Immunology
  BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses.
• BCX7353 · Immunology / Rare Disease
  BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.
• forodesine HCl

Phase 1 pipeline

• BCX-1777
• BCX10013
• BCX17725
• BCX4430
• BCX7353 and probes

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioCryst Pharmaceuticals portfolio CI brief
• BioCryst Pharmaceuticals pipeline updates RSS